CORRECTING and REPLACING: SergeFerrari Group announces 2024 full-year revenues of €323.6 million
Transform 2025 plan fully deployed
SAINT-JEAN-DE-SOUDAIN, France, January 30, 2025--(BUSINESS WIRE)--Regulatory News:
This replaces the announcement made at 5:45 PM CET on January 30th due to the following corrections: Amendment of two errors, one in the quote from Sébastien Baril, Chairman of the Executive Board, and the other in the first line of the last paragraph of the press release concerning the outlook.
SergeFerrari Group announces 2024 full-year revenues of €323.6 million
A dynamic Q4 2024, +13.6% vs Q4 2023, driven by an upturn in business across all zones (volume effect +22.3%)
Transform 2025 plan fully deployed
SergeFerrari Group (FR0011950682 - SEFER), one of the world leaders in innovative composite materials, listed on Euronext Paris - compartment C, today announced its revenue for the fourth quarter 2024 and full-year to the end of December 2024.
Revenues breakdown by geographical region (unaudited)
(€ thousands)
Q4 2024
Q4 2023
Ch. atcurrentscope andexchange rate
Ch. atconstantscope andexchangerate
FY 2024
FY 2023
Ch. atcurrentscope andexchangerate
Ch. atconstantscope andexchangerate
Europe
61,851
5,056
12.3%
11.3%
234,217
234,440
-0.1%
-0.2%
Americas
9,797
8,619
13.7%
14.3%
33,318
37,428
-11.0%
-10.6%
Asia – Africa – Pacific
18,160
15,381
18.1%
21.2%
56,102
55,771
-0.6%
2.1%
Total Revenues
89,807
79,056
13.6%
13.6%
323,637
327,639
-1.2%
-1.0%
Sébastien Baril, Chairman of the SergeFerrari Group's Executive Board, stated: "The revenues we are reporting for Q4 2024 confirm the upturn in business that began in Q2 2024, enabling us to achieve a level of full-year revenues comparable to that of 2023. As expected, during the year we deployed the final initiatives of the Transform 2025 plan, notably with the implementation of new synergies within the Group. In the second half of the year, the Group implemented a number of measures to mitigate the impact of tensions on certain raw materials, which will continue into 2025."
Activity as of December 31, 2024: revenues of €323.6 million
The Group reported revenues of €323.6 million for the full-year 2024, down slightly by -1.2% on a current consolidation scope and exchange rate basis, and by -1.0% on a constant basis. The level of business recorded over the 12 months confirms the gradual recovery in volumes observed since the end of the 1st half of 2024.
This global trend is the result of dynamics that remain highly contrasted according to the geographic zones addressed:
The Europe region has returned to the level of activity observed in 2023, with revenues almost on a par with the previous period, down -0.1% on a current consolidation scope and exchange rate basis, and -0.2% on a constant scope.
The Americas region continues to be penalized by a wait-and-see environment with the post-election transition in the United States and recorded a decline in revenues of -11.0% on a current consolidation scope and exchange rate, and -10.6% on a constant scope.
The Asia-Pacific-Middle East-Africa region posted revenues down slightly (-0.6%) at current exchange rates and reporting entity, but up 2.1% at constant exchange rates and reporting entity.
4th quarter 2024 activity: revenues of €89.8 million
Revenues for the 4th quarter 2024 amounted to €89.8 million, up +13.6% both on a current and constant scopes, compared with the 4th quarter 2023, boosted by the upturn in business across all the Group's geographical regions.
The global trend for this 4th quarter 2024 results from:
The Europe region that accelerated its recovery (+11.3%), driven by all its strategic markets;
The Americas region that is experiencing a significant recovery (+14.3%), mainly in the Tensile Architecture and Modular Structure markets;
The APMEA region, which marks the end of Tensile Architecture's product lag (+21.2%), more than offsetting the delay accumulated over the first 3 quarters of the year.
And consists of:
A price/mix effect of -8.7%;
The absence of any significant currency impact;
A strong volume effect, up +22.3%.
Outlook
Backed by the first positive impacts of the upturn in business during the second-half year, the Group intends to continue implementing the various operating efficiency measures set out in the Transform 2025 plan over the coming year. The full-year effects of this plan, combined with the current improvement in economic conditions in all our markets, confirm the Group's ambition to return rapidly to profitability.
Financial calendar
- Publication of 2024 Full-year results, on March 26, 2025, after market close.
ABOUT SERGEFERRARI GROUP
The Serge Ferrari Group is a leading global supplier of composite materials for Tensile Architecture, Modular Structures, Solar Protection and Furniture/Marine, in a global market estimated by the Company at around €6 billion. The unique characteristics of these products enable applications that meet the major technical and societal challenges: energy-efficient buildings, energy management, performance and durability of materials, concern for comfort and safety together, opening up of interior living spaces etc. Its main competitive advantage is based on the implementation of differentiating proprietary technologies and know-how. The Group has manufacturing facilities in France, Switzerland, Germany, Italy and Asia. Serge Ferrari operates in 80 countries via subsidiaries, sales offices and a worldwide network of over 100 independent distributors.
In 2024, Serge Ferrari posted consolidated revenues of €323.6 million, over 80% of which was generated outside France. The SergeFerrari Group share is listed on Euronext Paris – Compartment C (ISIN: FR0011950682). SergeFerrari Group shares are eligible for the French PEA-PME and FCPI investment schemes. www.sergeferrari.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130984342/en/
Contacts
Valentin Chefson Head of Relations Investisseursinvestor@sergeferrari.com
NewCap Investor Relations – Financial Communication Théo Martin / Nicolas FossiezTel.: +33 (0)1 44 71 94 94sferrari@newcap.eu
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Deadline Soon: 3D Systems Corporation (DDD) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON 3D SYSTEMS CORPORATION (DDD), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On March 26, 2025, 3D Systems released its fourth quarter and full year 2024 financial results, missing consensus estimates in non-GAAP earnings-per-share and sales revenue, citing 'lowers hardware systems sales due to macroeconomic factors that are negatively impacting demand.' The Company also reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program." The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing . . . which led to refinement of the milestone technical criteria." On this news, 3D Systems' stock price fell $0.57, or 21%, to close at $2.15 per share on March 27, 2025, thereby injuring investors. Then, on May 12, 2025, after market hours, 3D Systems released its first quarter 2025 financial results, missing consensus estimates due, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. The Company further disclosed that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68, or 26.6%, to close at $1.87 per share on May 13, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired 3D Systems securities between August 13, 2024 and May 12, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 12, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
19 minutes ago
- Business Wire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming August 11, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Rocket knew SAEs, including death of participants enrolled in the study, were a risk; (2) Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Rocket securities between September 17, 2024 and May 26, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 11, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
19 minutes ago
- Business Wire
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 29, 2025, Novo Nordisk cut its previously issued fiscal year 2025 guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Novo Nordisk securities during the Class Period, you may move the Court no later than September 30, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
